Literature DB >> 16015502

Overview of cancer epigenetics.

Peter A Jones1.   

Abstract

Epigenetic mechanisms including DNA and histone modifications result in silencing of genes without changing the coding sequence of the gene. Even though these events are heritable, they are potentially reversible, thus opening up opportunities for therapeutic intervention. The importance of epigenetic changes in human cancer is only now being recognized in the medical community. A series of discoveries over the last four decades has thrust epigenetics into the forefront of new drug discoveries. Three systems--DNA methylation, RNA-associated silencing, and histone modification--are used to initiate and sustain epigenetic silencing. Current knowledge suggests that agents that intervene in this process by "turning back on" silenced genes may represent a significant advancement in treating many forms of cancer. In addition, changed patterns of methylation can be detected with a high degree of sensitivity thus providing clinicians with prognostic information.

Entities:  

Mesh:

Year:  2005        PMID: 16015502     DOI: 10.1053/j.seminhematol.2005.05.001

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  22 in total

1.  Folate metabolism-related gene polymorphisms and susceptibility to primary liver cancer in North China.

Authors:  Lian-Hua Cui; Yang Song; Hongzong Si; Fangzhen Shen; Min-Ho Shin; Hee Nam Kim; Jin-Su Choi
Journal:  Med Oncol       Date:  2011-09-29       Impact factor: 3.064

2.  Lsh controls Hox gene silencing during development.

Authors:  Sichuan Xi; Heming Zhu; Hong Xu; Anja Schmidtmann; Theresa M Geiman; Kathrin Muegge
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-28       Impact factor: 11.205

Review 3.  Epigenetic regulation of EMT: the Snail story.

Authors:  Yiwei Lin; Chenfang Dong; Binhua P Zhou
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

4.  Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth.

Authors:  Chibo Hong; K Scott Moorefield; Peter Jun; Kenneth D Aldape; Samir Kharbanda; Heidi S Phillips; Joseph F Costello
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

5.  Differential Expression of Key Signaling Proteins in MCF10 Cell Lines, a Human Breast Cancer Progression Model.

Authors:  Jae Young So; Hong Jin Lee; Pavel Kramata; Audrey Minden; Nanjoo Suh
Journal:  Mol Cell Pharmacol       Date:  2012-01-01

6.  Array-based multiplex analysis of DNA methylation in breast cancer tissues.

Authors:  Anatoliy A Melnikov; Denise M Scholtens; Elizabeth L Wiley; Seema A Khan; Victor V Levenson
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

7.  Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast.

Authors:  Yunn-Yi Chen; Eun-Sil Shelley Hwang; Ritu Roy; Sandy DeVries; Joseph Anderson; Chrystal Wa; Patrick L Fitzgibbons; Timothy W Jacobs; Gaetan MacGrogan; Hans Peterse; Anne Vincent-Salomon; Taku Tokuyasu; Stuart J Schnitt; Frederic M Waldman
Journal:  Am J Surg Pathol       Date:  2009-11       Impact factor: 6.394

8.  TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia.

Authors:  Jianhua Yu; Maxim Ershler; Li Yu; Min Wei; Björn Hackanson; Akihiko Yokohama; Takeki Mitsui; Chunhui Liu; Hsiaoyin Mao; Shujun Liu; Zhongfa Liu; Rossana Trotta; Chang-gong Liu; Xiuping Liu; Kun Huang; Jan Visser; Guido Marcucci; Christoph Plass; Alexander V Belyavsky; Michael A Caligiuri
Journal:  Blood       Date:  2009-03-27       Impact factor: 22.113

9.  Human endometrial DNA methylome is cycle-dependent and is associated with gene expression regulation.

Authors:  Sahar Houshdaran; Zara Zelenko; Juan C Irwin; Linda C Giudice
Journal:  Mol Endocrinol       Date:  2014-05-30

Review 10.  Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma.

Authors:  Ernest C Borden
Journal:  Cytokine Growth Factor Rev       Date:  2007-08-06       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.